Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668725 | PMC |
| http://dx.doi.org/10.4103/0975-5950.168230 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Psychomotor therapy for individuals with mild intellectual disabilities or borderline intellectual functioning presenting anger regulation problems and/or aggressive behaviour: A qualitative study on clients' experiences.
J Intellect Dev Disabil
March 2022
Department Movement, Health and Wellbeing, Windesheim University of Applied Sciences, Zwolle, The Netherlands.
Background: Psychomotor therapy (PMT) is often applied in Dutch clinical practice to address aggressive behaviour in individuals with mild intellectual disabilities or borderline intellectual functioning. However, the literature on clients' experiences is lacking.
Methods: An interpretative phenomenological analysis was used to analyse the semi-structured interviews of seven participants (19-60 years; four male, three female) who completed PMT targeting anger regulation problems.
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.
Urol Oncol
January 2025
Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy; Department of Medical Oncology, IRCCS San Raffaele University, Milan, Italy.
Treatment options for recurrent high-risk non-muscle-invasive bladder cancer (HR NMIBC) and muscle-invasive bladder cancer (MIBC) are limited, highlighting a need for clinically effective, accessible, and better-tolerated alternatives. In this review we examine the clinical development program of TAR-200, a novel targeted releasing system designed to provide sustained intravesical delivery of gemcitabine to address the needs of patients with NMIBC and of those with MIBC. We describe the concept and design of TAR-200 and the clinical development of this gemcitabine intravesical system in the SunRISe portfolio of studies.
View Article and Find Full Text PDFBackground: Radiofrequency-assisted (RF) facial rejuvenation has become a safe and reliable option for "treatment gap" patients, including (1) patients whose skin laxity is not severe enough to warrant a facelift, yet not mild enough to reliably treat with noninvasive procedures; (2) patients who have already undergone a face or neck lift and have recurrent laxity; and (3) patients who would benefit from a traditional face or neck lift but want to avoid surgery and are willing to accept a more modest improvement without extensive surgical scar burden and recovery.
Objectives: In this study we aimed to educate the reader about providing bipolar RF to various anatomic regions of the face.
Methods: A retrospective review of cases was conducted to assess the safety of zone-specific RF-assisted facial rejuvenation in S.
Background: Acne is an inflammatory skin disease afflicting the majority of the world's population at some point in their lifetime, and is seen to be chronic in about 50% of cases. Acne leads to significant social withdrawal, depression, and disfiguring scars in many cases. Available treatments are characterized by high rates of relapse, dangerous side effects, and social stigma, which often leads to poor patient compliance and treatment failure.
View Article and Find Full Text PDFA Case Series With Cysteamine-Isobionicamide Complex: Clues for Skin-Rejuvenating Activity.
J Cosmet Dermatol
January 2025
Scientis SA, Geneva, Switzerland.
Background: Skin aging is inevitable. Wrinkles, skin texture abnormalities, senile hyperpigmentation, loss of skin tone, dryness, atrophy, and telangiectasias represent some of the hallmarks of aged skin. Skin rejuvenation can be addressed by topical therapies, such as topical retinoids and antioxidants or physical modalities with energy-based devices, all providing acceptable outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!